Galápagos NV has entered into an alliance with Roche to develop potential therapies for chronic obstructive pulmonary disease (COPD). Galápagos has received €6 million upfront and said potential milestone payments could exceed €400 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
